Search

In order to examine the transfer of antitumor drug in breast cancer after administration of FT-207 suppository, FT and 5-FU concentrations in blood, tumor tissues, normal tissues and axillary lymph nodes were determined respectively. FT and 5-FU concentrations in tumor tissues were higher than those in normal tissues or lymph nodes in every cases, and there was a significant difference between FT and 5-FU concentration in blood and tumor tissues. Blood levels of FT and 5-FU remained quite constant at 16 and 20 hours after administration, respectively. Accordingly, it was suggested that the administration of FT-207 suppository to breast cancer was very effective as an adjuvant chemotherapy.

The effects of a combined chemotherapy of solcoseryl and FT-207 on tumor growth, delayed hypersensitivity and cell population of the spleen were studied using inbred BALB/c mice. Meth-A tumor cells (2 X 10(6] were inoculated into the back of 5 to 6 week old BALB/c male mouse. Animals were divided into three groups: Solcoseryl group, in which 0.04 mg of solcoseryl was injected intravenously three times before inoculation and four times after inoculation; Combined group, in which 1.2 mg of FT-207 and 0.04 mg of solcoseryl were injected intravenously four times after inoculation; FT-207 group, in which 1.2 mg of FT-207 was injected four times after inoculation, with out solcoseryl administration. Following results were obtained: Solcoseryl group showed enhanced immunity and tumor suppression; Decreased immunity due to FT-207 was recovered by administration of solcoseryl but no tumor suppression was observed and, Decreased T-cell population of spleen due to FT-207 was recovered by administration of solcoseryl. These facts suggested that solcoseryl was useful because of making recovery possible from decreased immunity due to chemotherapy.

The peritoneal surface of the lesion was observed after treatment by scanning electron microscopy to evaluate the anticancer effect of FT-207. FT-207 (1.0 mg/day) was injected intraperitoneally to the DDN mice in which 3 X 10(7) MM2 tumor cells were inoculated the day before treatment. The anticancer effect was examined from 2nd to 7th consecutive day after tumor cell implantation, and the following results were obtained. 1) In the early phase after injection of FT-207, many macrophage-like cells were observed on the peritoneal surface. 2) Each MM2 tumor cell was covered by many macrophage-like cells, and these tumor cells were destroyed. 3) In the late phase after injection of FT-207, tumor cells were hyperplastic on the peritoneal surface, but less prominent than in the control group. 4) Effusion and adhesion in peritonitis carcinomatosa of FT-207 group were less than in the control group.